Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

Published:2017-05 Issue:5 Volume:18 Page:654-662
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rugo Hope S,Seneviratne Lasika,Beck J Thaddeus,Glaspy John A,Peguero Julio A,Pluard Timothy J,Dhillon Navneet,Hwang Leon Christopher,Nangia Chaitali,Mayer Ingrid A,Meiller Timothy F,Chambers Mark S,Sweetman Robert W,Sabo J Randy,Litton Jennifer K

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer;Lauring;J Natl Compr Canc Netw,2013

2. Afinitor (everolimus) prescribing information,2016

3. Stomatitis associated with use of mTOR inhibitors: implications for patients with invasive breast cancer;Divers;Clin J Oncol Nurs,2015

4. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2;Rugo;Ann Oncol,2014

5. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy;Rugo;Ann Oncol,2016

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tolerability and Safety of a New Oral Device for Enhancing Prevention and Treatment of Oral Mucositis in a Group of Patients with Hematologic Malignancies Undergoing Chemotherapy;2024-09-04

2. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer;Journal of Clinical Oncology;2024-09-01

3. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study;ESMO Open;2024-09

4. Wise and skillful utilization of contemporary endocrine therapies for the treatment of ER+/HER2– advanced breast cancer;Oncology in Clinical Practice;2024-08-21

5. Advances in Personalized Oncology;Cancers;2024-08-16